Belzutifan (PT2977, MK-6482) CAS:1672668-24-4

Belzutifan, also known as PT2977 or PT-2977, is a pharmaceutical compound that has been studied for its potential use in treating various cancers and other conditions. It is an oral hypoxia-inducible factor (HIF)-2α inhibitor, which can block the growth and proliferation of cancer cells. This article will provide an overview of Belzutifan, including its chemical properties, uses, health benefits, potential effects, safety, side effects, dosing information, and conclusion.

Chemical name:

(2S)-N-((1S)-2-amino-1-(4-chlorophenyl)ethyl)-1-(3-hydroxypropyl)-3-(4-(7-methoxyquinolin-4-yloxy)phenyl)propane-1-sulfonamide

Molecular formula:

C30H33ClN4O5S

Formula weight:

608.12 g/mol

CAS No:

1672668-24-4

Top ten keywords from Google and Synonyms:

1. Cancer - a group of diseases characterized by abnormal cell growth and division
2. Hypoxia-inducible factor (HIF) - a transcription factor involved in oxygen homeostasis and angiogenesis
3. Angiogenesis - the formation of new blood vessels, which can play a role in tumor growth and metastasis
4. Oncology - the study and treatment of cancer
5. Tumor - a mass or lump of abnormal cells
6. Renal cell carcinoma - a type of kidney cancer
7. Von Hippel-Lindau (VHL) syndrome - a genetic disorder associated with increased risk of kidney cancer and other tumors
8. Targeted therapy - medications or treatments that specifically target cancer cells or their mechanisms of growth
9. Prognosis - the likely course and outcome of a disease or condition
10. Anticancer agent - a substance that can inhibit or prevent the growth and spread of cancer cells.

Health benefits of this product:

The primary health benefit of Belzutifan is its potential use as an anticancer agent, particularly in the treatment of renal cell carcinoma and other tumors associated with HIF-2α overexpression. It may also have potential applications in other conditions involving hypoxia and angiogenesis.

Potential effects:

The potential effects of Belzutifan include inhibition of HIF-2α activity, reduction in tumor growth and proliferation, improved prognosis and survival rates in certain types of cancer, and potential applications in other conditions involving hypoxia and angiogenesis.

Product mechanism:

Belzutifan works by inhibiting the activity of HIF-2α, which plays a key role in regulating oxygen homeostasis and angiogenesis. By blocking HIF-2α activity, Belzutifan can slow or halt the growth and proliferation of cancer cells.

Safety:

Belzutifan is considered safe when used under medical supervision. However, it should not be used by individuals who are allergic to the compound or who have certain medical conditions. It is important to follow proper dosing instructions and consult with a healthcare professional before use.

Side effects:

The most common side effects of Belzutifan include fatigue, nausea, and decreased appetite. More serious side effects may include hypertension, blood clots, and bleeding. Individuals should seek medical attention immediately if they experience any of these side effects.

Dosing information:

The appropriate dosing of Belzutifan depends on the specific condition being treated and the individual patient's needs. It is important to follow recommended dosing guidelines provided by a healthcare professional.

Conclusion:

Belzutifan is a pharmaceutical compound that has been studied for its potential use in treating various cancers and other conditions associated with hypoxia and angiogenesis. While it can be effective in slowing or halting the growth and proliferation of cancer cells, it should only be used under the guidance of a healthcare professional. As with any medication, it is important to follow proper dosing instructions and monitor for potential side effects